RU2525915C2 - Антибактериальные соединения - Google Patents

Антибактериальные соединения Download PDF

Info

Publication number
RU2525915C2
RU2525915C2 RU2011127165/04A RU2011127165A RU2525915C2 RU 2525915 C2 RU2525915 C2 RU 2525915C2 RU 2011127165/04 A RU2011127165/04 A RU 2011127165/04A RU 2011127165 A RU2011127165 A RU 2011127165A RU 2525915 C2 RU2525915 C2 RU 2525915C2
Authority
RU
Russia
Prior art keywords
compounds
agents
compound
treatment
term
Prior art date
Application number
RU2011127165/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2011127165A (ru
Inventor
Фрэнсис Ксавье УИЛСОН
Питер Дейвид ДЖОНСОН
Ричард ВИКЕРС
Ричард Сторер
Грэхем Михаель УИННЕ
Алан Джеффри РОУЧ
МУР Оливье ДЕ
Колин Ричард ДОРГЕН
Пол Джеймс ДЕЙВИС
Original Assignee
Саммит Корпорейшн Плк
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Саммит Корпорейшн Плк filed Critical Саммит Корпорейшн Плк
Publication of RU2011127165A publication Critical patent/RU2011127165A/ru
Application granted granted Critical
Publication of RU2525915C2 publication Critical patent/RU2525915C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/20—Two benzimidazolyl-2 radicals linked together directly or via a hydrocarbon or substituted hydrocarbon radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
RU2011127165/04A 2008-12-02 2009-12-01 Антибактериальные соединения RU2525915C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0821913.1 2008-12-02
GBGB0821913.1A GB0821913D0 (en) 2008-12-02 2008-12-02 Antibacterial compounds
PCT/GB2009/002792 WO2010063996A2 (en) 2008-12-02 2009-12-01 Antibacterial compounds

Publications (2)

Publication Number Publication Date
RU2011127165A RU2011127165A (ru) 2013-01-10
RU2525915C2 true RU2525915C2 (ru) 2014-08-20

Family

ID=40262471

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2011127165/04A RU2525915C2 (ru) 2008-12-02 2009-12-01 Антибактериальные соединения

Country Status (27)

Country Link
US (3) US8975416B2 (enExample)
EP (3) EP2907813B1 (enExample)
JP (3) JP5665756B2 (enExample)
KR (1) KR101643435B1 (enExample)
CN (1) CN102227411B (enExample)
AU (1) AU2009323854B2 (enExample)
BR (2) BR122020013025B1 (enExample)
CA (1) CA2744962C (enExample)
CY (2) CY1116383T1 (enExample)
DK (2) DK2373631T3 (enExample)
ES (2) ES2575908T3 (enExample)
GB (1) GB0821913D0 (enExample)
HR (2) HRP20150518T1 (enExample)
HU (1) HUE029151T2 (enExample)
IL (1) IL213325A (enExample)
LT (1) LT2907813T (enExample)
MX (1) MX2011005837A (enExample)
NZ (1) NZ593111A (enExample)
PL (2) PL2907813T3 (enExample)
PT (2) PT2907813T (enExample)
RS (1) RS54904B1 (enExample)
RU (1) RU2525915C2 (enExample)
SG (1) SG171939A1 (enExample)
SI (2) SI2907813T1 (enExample)
SM (2) SMT201500117B (enExample)
WO (1) WO2010063996A2 (enExample)
ZA (1) ZA201103751B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2844553C2 (ru) * 2019-07-17 2025-08-04 Саммит (Оксфорд) Лимитед Способ получения ридинилазола и его кристаллических форм

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0821913D0 (en) 2008-12-02 2009-01-07 Price & Co Antibacterial compounds
WO2011151620A1 (en) * 2010-06-01 2011-12-08 Summit Corporation Plc Compounds for the treatment of clostridium difficile associated disease
GB2480814A (en) * 2010-06-01 2011-12-07 Summit Corp Plc Compounds for the treatment of clostridium difficile-associated disease
WO2011151619A1 (en) * 2010-06-01 2011-12-08 Summit Corporation Plc Compounds for the treatment of clostridium difficile associated disease
SI2575968T1 (sl) * 2010-06-01 2016-06-30 Summit Therapeutics Plc Spojine za zdravljenje bolezni, ki je povezana s clostridium difficile
GB2480816A (en) * 2010-06-01 2011-12-07 Summit Corp Plc Compounds for the treatment of Clostridium difficile associated diseases
GB2480813A (en) * 2010-06-01 2011-12-07 Summit Corp Plc Compounds for the treatment of clostridium difficile-associated disease
US9079935B2 (en) 2012-08-13 2015-07-14 The Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Las Vegas Reducing risk of contracting Clostridium-difficile associated disease
FI3628161T3 (fi) 2012-11-23 2023-05-25 Seres Therapeutics Inc Synergisiä bakteerikoostumuksia ja niiden valmistusmenetelmiä ja käyttö
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
HK1218560A1 (zh) 2013-02-04 2017-02-24 Seres Therapeutics, Inc. 组成与方法
US11185562B2 (en) 2013-02-04 2021-11-30 Seres Therapeutics, Inc. Compositions and methods for inhibition of pathogenic bacterial growth
US10076546B2 (en) 2013-03-15 2018-09-18 Seres Therapeutics, Inc. Network-based microbial compositions and methods
CA2931317C (en) 2013-11-25 2023-08-22 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
WO2015095241A2 (en) 2013-12-16 2015-06-25 Seres Health, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
JP6526956B2 (ja) * 2013-12-19 2019-06-05 花王株式会社 固形状組成物
US9717711B2 (en) 2014-06-16 2017-08-01 The Lauridsen Group Methods and compositions for treating Clostridium difficile associated disease
US20180000793A1 (en) 2015-02-06 2018-01-04 Ernesto Abel-Santos Inhibiting Germination of Clostridium Perfringens Spores to Reduce Necrotic Enteritis
MX2020001774A (es) 2017-08-14 2020-09-09 Seres Therapeutics Inc Composiciones y métodos para tratar enfermedad colestásica.
EP3692030B1 (en) * 2017-10-05 2023-04-19 Sandoz AG Process for the preparation of ridinilazole using acid addition salts
RU2020117775A (ru) 2017-10-30 2021-12-01 Серес Терапеутикс, Инк. Композиции и способы для лечения устойчивости к антибиотикам
EP3999502A1 (en) 2019-07-17 2022-05-25 Summit (Oxford) Limited Process for the preparation of ridinilazole and crystalline forms thereof
CR20220316A (es) 2019-12-06 2022-10-07 Vertex Pharma Tetrahidrofuranos sustituidos como moduladores de canales de sodio
US20210324009A1 (en) * 2020-04-17 2021-10-21 The University Of Hong Kong Anti-bacterial calcium-dependent antibiotic (cda) analogs and methods of treating bacterial infections
GB202100470D0 (en) * 2021-01-14 2021-03-03 Summit Oxford Ltd Solid tablet dosage for of ridinilazole
GB202100471D0 (en) 2021-01-14 2021-03-03 Summit Oxford Ltd Preparation of antibacterial compounds
EP4346799A4 (en) * 2021-05-24 2025-04-09 Aimmax Therapeutics, Inc. Pristinamycin ia and flopristin combinations in treating or preventing bacterial infections
JP2024522292A (ja) 2021-06-04 2024-06-13 バーテックス ファーマシューティカルズ インコーポレイテッド ナトリウムチャネルのモジュレーターとしてのｎ－（ヒドロキシアルキル（ヘテロ）アリール）テトラヒドロフランカルボキサミド
CR20230576A (es) 2021-06-14 2024-04-05 Scorpion Therapeutics Inc Derivados de la urea que pueden ser utilizados para tratar el cáncer
US12220421B2 (en) 2021-09-09 2025-02-11 The Boards Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Las Inhibitors of C. difficile spore germination
WO2024112631A1 (en) * 2022-11-22 2024-05-30 Aimmax Therapeutics, Inc. Streptogramin a monotherapy for treating or preventing bacterial infections
EP4418810A1 (de) 2023-02-15 2024-08-21 Siemens Aktiengesellschaft Verfahren zur rechnergestützten überwachung einer industriellen anlage mittels eines funknetzes

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1547996A1 (en) * 2002-08-30 2005-06-29 BF Research Institute, Inc. Diagnostic probes and remedies for diseases with accumulation of prion protein, and stains for prion protein

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3661849A (en) * 1965-10-06 1972-05-09 Ashland Oil Inc Heterocyclic polyimides prepared from heterocyclic diamines
US3503929A (en) * 1965-10-21 1970-03-31 Minnesota Mining & Mfg Polyimidazoquinazolines and polyamidobenzimidazoles
DE1670684A1 (de) 1966-04-01 1970-12-03 Hoechst Ag Verfahren zur Herstellung von basisch substituierten Bis-benzimidazol-derivaten
US4087409A (en) 1966-11-07 1978-05-02 Monsanto Company Ordered heterocyclic copolymers
JPS50140445A (enExample) * 1974-04-30 1975-11-11
JPS50154250A (enExample) * 1974-05-31 1975-12-12
US5089592A (en) 1988-06-09 1992-02-18 The Dow Chemical Company Biscyclobutarene monomer comprising two cyclobutarene moieties bridged by a divalent radical comprising at least one benzothiazole or benzimidazole linkage
JPH03500661A (ja) * 1988-06-09 1991-02-14 ザ・ダウ・ケミカル・カンパニー ベンゾキサゾール，ベンゾチアゾールまたはベンズイミダゾールの少なくとも１つの結合によって架橋したビスシクロブタレンのモノマー，オリゴマー及びポリマー
GB9108279D0 (en) 1991-04-18 1991-06-05 Ucb Sa A method of preparing 1h-benzimidazoles
US5317078A (en) 1991-10-30 1994-05-31 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Polybenzimidazole via aromatic nucleophilic displacement
CN1164227A (zh) 1994-11-17 1997-11-05 弗·哈夫曼-拉罗切有限公司 联苯并咪唑衍生物
CA2204639A1 (en) 1994-11-17 1996-05-30 Werner Leupin Antibacterial dibenzimidazole derivatives
US5770617A (en) 1996-03-20 1998-06-23 Rutgers, The State University Of New Jersey Terbenzimidazoles useful as antifungal agents
JPH11158156A (ja) 1997-12-03 1999-06-15 Earth Chem Corp Ltd 新規な１−（４−アルキルオキシフェニル）イミダゾール化合物
JPH11158158A (ja) * 1997-12-03 1999-06-15 Snow Brand Milk Prod Co Ltd 新規ベンゾイミダゾール誘導体
US6358930B1 (en) 1998-05-28 2002-03-19 Synsorb Biotech Inc. Treatment of C. difficile toxin B associated conditions
JP2000095767A (ja) * 1998-09-28 2000-04-04 Takeda Chem Ind Ltd 性腺刺激ホルモン放出ホルモン拮抗剤
GB9908828D0 (en) 1999-04-16 1999-06-16 Univ Reading The Compounds
AU2002218309A1 (en) 2000-11-27 2002-06-03 Ciba Specialty Chemicals Holding Inc. Substituted 5-aryl and 5-heteroaryl-2-(2-hydroxyphenyl)-2h-benzotriazole derivatives as uv absorbers
SI1341769T1 (sl) 2000-12-15 2008-02-29 Vertex Pharma Inhibitorji bakterijske giraze in njihove uporabe
FR2819180B1 (fr) 2001-01-11 2003-02-21 Oreal Composition photoprotectrices a base de polymeres amphiphiles d'au moins un monomere a insaturation ethylique a groupement sulfonique et comportant une partie hydrophobe
WO2002060374A2 (en) * 2001-01-29 2002-08-08 Insight Strategy And Marketing Ltd Benz-1,3-azole derivatives and their uses as heparanase inhibitors
CA2445515A1 (en) 2001-05-04 2002-11-04 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
WO2003007955A2 (en) * 2001-07-20 2003-01-30 Cancer Research Technology Limited Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
EP1441725A1 (en) 2001-10-26 2004-08-04 Aventis Pharmaceuticals Inc. Benzimidazoles and analogues and their use as protein kinases inhibitors
CA2489128C (en) 2002-06-13 2012-01-03 Vertex Pharmaceuticals Incorporated 2-ureido-6-heteroaryl-3h-benzoimidazole-4-carboxylic acid derivatives and related compounds as gyrase and/or topoisomerase iv inhibitors for the treatment of bacterial infections
WO2004041209A2 (en) 2002-11-01 2004-05-21 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
US20060160799A1 (en) 2004-04-23 2006-07-20 Alekshun Michael N Transcription factor modulating compounds and methods of use thereof
KR100629060B1 (ko) 2004-08-11 2006-09-26 주식회사 엘지화학 새로운 벤즈이미다졸계 화합물
US7528138B2 (en) 2004-11-04 2009-05-05 Vertex Pharmaceuticals Incorporated Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases
WO2006077412A1 (en) 2005-01-19 2006-07-27 Biolipox Ab Thienopyrroles useful in the treatment of inflammation
JP5390186B2 (ja) 2005-08-12 2014-01-15 ユナイテッド ステイツ ガバメント アズ レプリゼンティッド バイ ザ セクレタリー オブ ザ ユナイテッド ステイツ アーミー アンド ザ ユーエス アーミー メディカル リサーチ アンド マティリ 広い抗菌スペクトルを有する抗菌性化合物
CN101321744A (zh) 2005-11-07 2008-12-10 沃泰克斯药物股份有限公司 作为回旋酶抑制剂的苯并咪唑衍生物
KR100744827B1 (ko) * 2006-04-05 2007-08-01 한국화학연구원 트리플루오로비닐옥시기를 포함하는 불소계 벤즈이미다졸 단량체 및 이의 제조방법
GB0612428D0 (en) 2006-06-22 2006-08-02 Prolysis Ltd Antibacterial agents
MX2009002171A (es) 2006-08-30 2009-05-28 Cellzome Ltd Derivados de triazol como inhibidores de cinasas.
AR063311A1 (es) 2006-10-18 2009-01-21 Novartis Ag Compuestos organicos
WO2008073451A2 (en) 2006-12-11 2008-06-19 Sirtris Pharmaceuticals, Inc. Benzoimidazole derivatives as sirtuin (sir) modulating compounds
CA2672815A1 (en) 2006-12-15 2008-06-26 Pfizer Products Inc. Benzimidazole derivatives for use in treating abnormal cell growth
ES2526966T3 (es) 2008-06-05 2015-01-19 Glaxo Group Limited Compuestos novedosos
KR101022649B1 (ko) 2008-08-07 2011-03-22 삼성모바일디스플레이주식회사 헤테로고리 화합물 및 이를 이용한 유기 전계 발광 장치
US7906655B2 (en) 2008-08-07 2011-03-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
GB0821913D0 (en) * 2008-12-02 2009-01-07 Price & Co Antibacterial compounds
CA2753382C (en) 2009-02-27 2014-12-23 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
KR101219487B1 (ko) 2009-03-03 2013-01-15 덕산하이메탈(주) 비스벤조이미다졸 화합물 및 이를 이용한 유기전기소자, 그단말
HUE027964T2 (en) 2009-04-02 2016-11-28 Fund Centro Nac De Investig Oncologicas Carlos Iii Imidazo [2,1-b] [1,3,4] thiadiazole derivatives
WO2010138575A1 (en) 2009-05-27 2010-12-02 Abbott Laboratories Pyrimidine inhibitors of kinase activity
EP2435424B1 (en) 2009-05-29 2015-01-21 Merck Sharp & Dohme Corp. Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c
US8377945B2 (en) 2009-06-15 2013-02-19 Rigel Pharmaceuticals Inc. Small molecule inhibitors of spleen tyrosine kinase (SYK)
CN102656141B (zh) 2009-10-13 2016-04-06 利亘制药公司 模拟造血生长因子的小分子化合物及其用途
SI2575968T1 (sl) 2010-06-01 2016-06-30 Summit Therapeutics Plc Spojine za zdravljenje bolezni, ki je povezana s clostridium difficile

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1547996A1 (en) * 2002-08-30 2005-06-29 BF Research Institute, Inc. Diagnostic probes and remedies for diseases with accumulation of prion protein, and stains for prion protein

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Brand R.A. et al: "Oligomeric benzimidazoles with reactive end groups", Journal of polymer science: Polymer chemistry edition, vol.17, pp.1145-1152 . *
Srivastava R.P. et al: "Studies in antiparasitic agents: Part 20 "Synthesis of probenzimidazoles, benzimidazoles and pyrimido[1,2-a]benzimidazoles as possible anthelmintics", Indian journal of chemistry, vol.32B, 10.1993, pp.1035-1044 . Chaudhuri P. et al: "An experimental and computational analysis on the differential role of the positional isomers of symmetric bis-2-(pyridyl)-1H-benzimidazoles as DNA binding agents", J.Org.Chem., 2007, vol.72, no.6, pp.1912-1923 . Rigault S.: "Lanthanide-assisted self-assembly of an inert metal-containing nonadentate tripodal receptor", Angew.Chem.Int.Ed., 1998, vol.37, no.1/2 pp.169-172 . Hao, J.Z. et al: "Convenient synthesis of 2-arylbenzimidazoles and 2,2'-diaryl-bisbenzimidazoles", Synthetic communications, vol.33, no.1, pp.79-86, 2003. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2844553C2 (ru) * 2019-07-17 2025-08-04 Саммит (Оксфорд) Лимитед Способ получения ридинилазола и его кристаллических форм

Also Published As

Publication number Publication date
US20160184283A1 (en) 2016-06-30
BRPI0922220B8 (pt) 2021-05-25
AU2009323854A2 (en) 2011-06-30
SMT201600259B (it) 2016-08-31
EP2907813A1 (en) 2015-08-19
CA2744962C (en) 2017-06-06
ZA201103751B (en) 2014-10-29
GB0821913D0 (en) 2009-01-07
JP2012510458A (ja) 2012-05-10
HRP20160597T1 (hr) 2016-09-23
SMT201500117B (it) 2015-07-09
DK2373631T3 (en) 2015-05-26
KR101643435B1 (ko) 2016-07-27
US8975416B2 (en) 2015-03-10
PT2373631E (pt) 2015-06-09
CA2744962A1 (en) 2010-06-10
RS54904B1 (sr) 2016-10-31
DK2907813T3 (en) 2016-07-25
PL2373631T3 (pl) 2015-10-30
CY1117934T1 (el) 2017-05-17
NZ593111A (en) 2013-05-31
BRPI0922220A8 (pt) 2018-04-03
HK1208668A1 (en) 2016-03-11
LT2907813T (lt) 2016-10-10
US20150150861A1 (en) 2015-06-04
JP5665756B2 (ja) 2015-02-04
JP2017048217A (ja) 2017-03-09
ES2575908T3 (es) 2016-07-04
US20120020950A1 (en) 2012-01-26
US9314456B2 (en) 2016-04-19
AU2009323854A1 (en) 2010-06-10
WO2010063996A3 (en) 2010-12-29
BR122020013025B1 (pt) 2021-05-18
EP2907813B1 (en) 2016-04-27
EP3095783A1 (en) 2016-11-23
PL2907813T3 (pl) 2016-09-30
BRPI0922220A2 (pt) 2015-12-29
SI2373631T1 (sl) 2015-08-31
MX2011005837A (es) 2011-11-18
EP2373631B1 (en) 2015-02-25
PT2907813T (pt) 2016-08-05
HRP20150518T1 (hr) 2015-07-17
US9763925B2 (en) 2017-09-19
IL213325A (en) 2016-02-29
WO2010063996A2 (en) 2010-06-10
EP2373631A2 (en) 2011-10-12
CY1116383T1 (el) 2017-02-08
CN102227411A (zh) 2011-10-26
HUE029151T2 (hu) 2017-02-28
RU2011127165A (ru) 2013-01-10
KR20110093925A (ko) 2011-08-18
JP2015078220A (ja) 2015-04-23
IL213325A0 (en) 2011-07-31
BRPI0922220B1 (pt) 2021-03-09
HK1162169A1 (en) 2012-08-24
SI2907813T1 (sl) 2016-09-30
ES2537059T3 (es) 2015-06-02
AU2009323854B2 (en) 2014-06-26
SG171939A1 (en) 2011-07-28
CN102227411B (zh) 2015-10-14

Similar Documents

Publication Publication Date Title
RU2525915C2 (ru) Антибактериальные соединения
JP6150841B2 (ja) クロストリジウム・ディフィシル関連疾患を治療するための化合物
WO2011151619A1 (en) Compounds for the treatment of clostridium difficile associated disease
RU2575477C2 (ru) Соединения для лечения заболеваний, связанных с clostridium difficile
HK1227868A (en) Antibacterial compositions
HK1227868A1 (en) Antibacterial compositions
WO2011151617A1 (en) Compounds for the treatment of clostridium difficile associated disease
HK1177706B (en) Compounds for the treatment of clostridium difficile associated disease

Legal Events

Date Code Title Description
PD4A Correction of name of patent owner
PC41 Official registration of the transfer of exclusive right

Effective date: 20180820